Macugen: Withdrawal of the application to change the marketing authorisation
pegaptanib
Table of contents
Overview
On 15 July 2011, Pfizer officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication, the treatment of visual impairment due to diabetic macular oedema.
Key facts
Name |
Macugen |
Product number |
EMEA/H/C/000620 |
Date of issue of market authorisation valid throughout the European Union (if applicable) |
31/01/2006 |
International non-proprietary name (INN) or common name |
|
Active substance |
|
Date of withdrawal |
15/07/2011 |
Company making the application | |
Withdrawal type |
Post-authorisation |
All documents
-
List item
Withdrawal assessment report for Macugen (PDF/2.97 MB)
Adopted
First published: 29/09/2011
Last updated: 29/09/2011
EMA/737688/2011 -
List item
Macugen: Withdrawal letter (PDF/139.87 KB)
First published: 27/07/2011
Last updated: 27/07/2011 -
List item
Pfizer Limited withdraws its application for an extension of the indication for Macugen (pegaptanib sodium) (PDF/95.36 KB)
First published: 19/07/2011
Last updated: 19/07/2011
EMA/567717/2011 -
List item
Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Macugen (pegaptanib) (PDF/65.01 KB)
First published: 27/07/2011
Last updated: 27/07/2011
EMA/CHMP/563649/2011
Related information on withdrawals
The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').